Evaluation of inactivated hepatitis A vaccine in Canadians 40 years of age or more.
OBJECTIVE
To assess the side effects and immune responses after three serial doses of a new inactivated hepatitis A vaccine in people 40 years of age or more.


METHODS
Open, noncomparative trial.


METHODS
A hospital, a regional laboratory and public health units in British Columbia.


METHODS
A volunteer sample of 64 healthy adults aged 40 to 61 years who were seronegative for hepatitis A virus (HAV). All were staff or associates of the health facilities. Exclusion criteria included elevated serum alanine and aspartate aminotransferase levels, a history of liver disease and recent travel to areas of high risk for HAV infection.


METHODS
A formalin-inactivated, alum-adsorbed vaccine containing 720 ELISA (enzyme-linked immunosorbent assay) units of antigen from HAV strain HM175 per 1.0-mL dose was injected intramuscularly into the delgoid area. The second and third doses were given 1 and 6 months later respectively.


METHODS
A detailed diary of any adverse effects for 3 days after each dose. HAV antibody levels in blood samples taken before and 30 days after each dose.


RESULTS
All subjects completed the planned series of vaccinations and blood tests; symptom diaries were returned after 190 (99%) of 192 vaccinations. Local symptoms, most often soreness, were reported after 46% of the vaccinations but were mild and usually resolved within 24 hours. A temperature of more than 38.0 degrees C was never reported. Seroconversion occurred in all cases after the two primary doses, and the subjects were still seropositive at 6 months. After the booster dose the geometric mean titre was 2380 mIU/mL, all values being 200 mIU/mL or greater.


CONCLUSIONS
In healthy adults 40 years of age or more the HAV vaccine was well tolerated and highly immunogenic. Final antibody levels were much higher than reported in people passively immunized against HAV with immune serum globulin.
Scheifele
D W
DW
Department of Pediatrics, British Columbia's Children's Hospital, Vancouver.
Bjornson
G J
GJ
D000328:Adult; D000367:Age Factors; D000917:Antibody Formation; D001955:British Columbia / Q000453:epidemiology; D004342:Drug Hypersensitivity / Q000453:epidemiology / Q000209:etiology; D005260:Female; D006506:Hepatitis A / Q000276:immunology; D022362:Hepatitis A Vaccines; D006508:Hepatitis Antibodies / Q000097:blood; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D014761:Viral Hepatitis Vaccines / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*
D022362:Hepatitis A Vaccines; D006508:Hepatitis Antibodies; D014761:Viral Hepatitis Vaccines